alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Newest studies

Every summary in our library, newest first, as a dated timeline.

What "newest" means here

The most recent study in this library is dated 2026-11-01 (Paths of Aging Minds: Health Journeys of Older Adults with Mild Cognitive Impairment). This is our summary library, not a news wire — it is added to in batches, so the newest entry may not be the newest paper published anywhere.

Entries are sorted strictly by publication date, newest first. 26489 of the 27380 entries carry a full day-level date. 65 have no date recorded at all and are placed by publication year, at the start of that year; those are marked "no date recorded" below so you can see where the ordering is a best effort rather than a fact.

Prefer a reader? Subscribe to the Atom feed. Want them sorted by subject or by score instead? Browse the research library.

Showing 26,651–26,675 of 27,380 studies, newest first · page 1067 of 1096.

June 1994 3

  1. 1994-06-01

    Astrocytosis and axonal proliferation in the hippocampus of S100b transgenic mice

    ✓ Peer-reviewed Down syndrome and Alzheimer's Proceedings of the National Academy of Sciences of the United States of America

    Key finding: Expression in both lines is cell type- and tissue-appropriate, and expression levels are correlated with the transgene copy number, demonstrating that sequences necessary for normal regulation of the gene are included within the cloned segment. +4 more findings

    Full summary, score breakdown and related studies → Original source

  2. 1994-06-01

    The syndrome of 'pure akinesia' and its relationship to progressive supranuclear palsy

    ✓ Peer-reviewed Digital health tools Neurology

    Key finding: These clinical findings conform to a syndrome described repeatedly in Japan since 1974 as "pure akinesia." +2 more findings

    Full summary, score breakdown and related studies → Original source

  3. 1994-06-01

    Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease

    ✓ Peer-reviewed Genetics Nature genetics

    Key finding: Gene dosage of the apolipoprotein E (APOE) epsilon 4 allele is a major risk factor for familial Alzheimer disease (AD) of late onset (after age 60). +4 more findings

    Full summary, score breakdown and related studies → Original source

May 1994 16

  1. 1994-05-27

    An Increased Percentage of Long Amyloid β Protein Secreted by Familial Amyloid β Protein Precursor (βApp 717 ) Mutants

    ✓ Peer-reviewed Risk genes beyond APOE Science

    Normal processing of the amyloid beta protein precursor (beta APP) results in secretion of a soluble 4-kilodalton protein essentially identical to the amyloid beta protein (A beta) that forms insoluble fibrillar deposits in Alzheimer's disease.

    Full summary, score breakdown and related studies → Original source

  2. 1994-05-01

    Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease

    ✓ Peer-reviewed Disease mechanisms Annals of Neurology

    Key finding: The concentrations of both transporters were reduced in the cerebral cortex, with larger and highly significant reductions observed for GLUT3, the putative neuronal glucose transporter.

    Full summary, score breakdown and related studies → Original source

  3. 1994-05-01

    A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats

    ✓ Peer-reviewed Disparities The New England journal of medicine

    Key finding: CAG trinucleotide expansion is the molecular basis of Huntington's disease worldwide and is a highly sensitive and specific marker for inheritance of the disease mutation. +3 more findings

    Full summary, score breakdown and related studies → Original source

  4. 1994-05-01

    Identification of two distinct synucleins from human brain

    ✓ Peer-reviewed Brain tissue and pathology FEBS letters

    Key finding: The 140 amino acid protein is identical with the precursor of the non-A beta component of Alzheimer's disease amyloid which in turn is highly homologous to synuclein from Torpedo electroplaques and rat brain. +4 more findings

    Full summary, score breakdown and related studies → Original source

  5. 1994-05-01

    Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro

    ✓ Peer-reviewed Genetics Science (New York, N.Y.)

    Key finding: The data suggest that receptor-mediated binding or internalization (or both) of apoE-enriched beta-VLDL leads to isoform-specific differences in interactions with cellular proteins that affect neurite outgrowth.

    Full summary, score breakdown and related studies → Original source

  6. 1994-05-01

    Psychiatric comorbidity and length of stay in the general hospital. A critical review of outcome studies

    ✓ Peer-reviewed Clinical safety Psychosomatics

    Key finding: Eighty-nine percent of all studies with sample sizes greater than 110 and 75% of the prospective, rigorously controlled, American studies found a significant association between psychiatric comorbidity and increased length of stay. +1 more finding

    Full summary, score breakdown and related studies → Original source

  7. 1994-05-01

    Advanced glycation end products contribute to amyloidosis in Alzheimer disease

    ✓ Peer-reviewed Disease mechanisms Proceedings of the National Academy of Sciences of the United States of America

    Key finding: AGE-modified beta AP-nucleation seeds further accelerated aggregation of soluble beta AP compared to non-modified "seed" material. +2 more findings

    Full summary, score breakdown and related studies → Original source

  8. 1994-05-01

    Epidemiology and comorbidity of anxiety disorders in the elderly

    ✓ Peer-reviewed Brain tissue and pathology The American journal of psychiatry

    Key finding: The author reviewed the epidemiology and comorbidity of anxiety disorders in the elderly. +3 more findings

    Full summary, score breakdown and related studies → Original source

  9. 1994-05-01

    Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer's disease

    ✓ Peer-reviewed Brain tissue and pathology Nature genetics

    Key finding: Here we report on the relationship between APOE*4 and early-onset Alzheimer's disease (EOAD) in a Dutch population-based study. +3 more findings

    Full summary, score breakdown and related studies → Original source

  10. 1994-05-01

    Soluble amyloid beta-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid

    ✓ Peer-reviewed Risk genes beyond APOE Biochemical and biophysical research communications

    Key finding: Soluble A beta is a normal metabolic product and is present in cerebrospinal fluid. +3 more findings

    Full summary, score breakdown and related studies → Original source

  11. 1994-05-01

    Morphologic and biochemical analysis of the intracellular trafficking of the Alzheimer beta/A4 amyloid precursor protein

    ✓ Peer-reviewed Risk genes beyond APOE The Journal of neuroscience : the official journal of the Society for Neuroscience

    Key finding: Several aspects of normal APP processing have been elucidated, but the precise cellular trafficking of APP remains unclear. +3 more findings

    Full summary, score breakdown and related studies → Original source

  12. 1994-05-01

    Estrogen regulates metabolism of Alzheimer amyloid beta precursor protein

    ✓ Peer-reviewed Risk genes beyond APOE The Journal of biological chemistry

    Key finding: Using a cell line that contains high levels of estrogen receptors, we have found that treatment with physiological concentrations of 17 beta-estradiol is associated with accumulation in the conditioned medium of an amino-terminal cleavage product of APP (soluble APP or protease nexin-2), indicative of non-amyloidogenic processing. +1 more finding

    Full summary, score breakdown and related studies → Original source

  13. 1994-05-01

    The evolution of ovarian oocyte decline with aging and possible relationships to Down syndrome and Alzheimer disease

    ✓ Peer-reviewed Down syndrome and Alzheimer's Experimental gerontology

    Key finding: Second, studies on mice suggest that the maternal age effect that accelerates the incidence of Down syndrome is due not to age per se but to dwindling ovarian oocyte pools.

    Full summary, score breakdown and related studies → Original source

  14. 1994-05-01

    Down syndrome phenotypes: the consequences of chromosomal imbalance

    ✓ Peer-reviewed Down syndrome and Alzheimer's Proceedings of the National Academy of Sciences of the United States of America

    Key finding: Besides a characteristic set of facial and physical features, DS is associated with congenital anomalies of the gastrointestinal tract, an increased risk of leukemia, immune system defects, and an Alzheimer-like dementia. +1 more finding

    Full summary, score breakdown and related studies → Original source

  15. 1994-05-01

    An evaluation of the predictive validity and inter-rater reliability of clinical diagnostic criteria for senile dementia of Lewy body type

    ✓ Peer-reviewed Disparities Neurology

    Key finding: Several recent autopsy studies suggest that senile dementia of Lewy body type (SDLT) may be the second most common neuropathologic cause of dementia in the elderly, accounting for 7 to 30% of all cases.

    Full summary, score breakdown and related studies → Original source

  16. 1994-05-01

    Idebenone, a new drug in the treatment of cognitive impairment in patients with dementia of the Alzheimer type

    ✓ Peer-reviewed Treatments Functional neurology

    Key finding: The most common side effects associated with this treatment were insomnia, gastralgia, nausea, and anxiety.

    Full summary, score breakdown and related studies → Original source

April 1994 6

  1. 1994-04-06

    Hepatotoxic Effects of Tacrine Administration in Patients With Alzheimer's Disease

    ✓ Peer-reviewed How common it is JAMA

    Key finding: Among the 2446 patients who received tacrine in clinical trials, ALT levels greater than the upper limit of normal (ULN) occurred on at least one occasion in 1203 patients (49%), ALT levels greater than three times the ULN occurred in 621 patients (25%), and ALT levels greater than 20 times the ULN occurred in 40 patients (2%). +4 more findings

    Full summary, score breakdown and related studies → Original source

  2. 1994-04-01

    Modulation of A beta adhesiveness and secretase site cleavage by zinc

    ✓ Peer-reviewed Down syndrome and Alzheimer's The Journal of biological chemistry

    Key finding: Zinc binding also increased A beta resistance to tryptic cleavage at the secretase site, indicating that a small (<3 microM) increase in brain Zn2+ concentration could significantly alter A beta metabolism.

    Full summary, score breakdown and related studies → Original source

  3. 1994-04-01

    Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus

    ✓ Peer-reviewed Risk factors Nature

    Key finding: These findings indicate that amylin fibril formation in the pancreas may cause islet cell dysfunction and death in type-2 diabetes mellitus.

    Full summary, score breakdown and related studies → Original source

  4. 1994-04-01

    A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group

    ✓ Peer-reviewed Clinical trials JAMA

    Key finding: Tacrine produced statistically significant, dose-related improvements on objective performance-based tests, clinician- and caregiver-rated global evaluations, and measures of quality of life. +4 more findings

    Full summary, score breakdown and related studies → Original source

  5. 1994-04-01

    Incidence of dementia in a population older than 75 years in the United Kingdom

    ✓ Peer-reviewed Clinical safety Archives of general psychiatry

    Key finding: The findings show high rates of new onset dementia, increasing markedly with age, and suggest rapid acceleration of one or more processes that is common in advanced age. +1 more finding

    Full summary, score breakdown and related studies → Original source

  6. 1994-04-01

    The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery

    ✓ Peer-reviewed Cognitive tests and assessment Neurology

    The neuropsychological tests developed for the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) are currently used to measure cognitive impairments of Alzheimer's disease (AD) in clinical investigations of this disorder.

    Full summary, score breakdown and related studies → Original source

Browse the library by subject, with the full score breakdown →